-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
DICE Therapeutics (NASDAQ:DICE) Shares Gap Down to $19.09
DICE Therapeutics (NASDAQ:DICE) Shares Gap Down to $19.09
DICE Therapeutics, Inc. (NASDAQ:DICE – Get Rating) gapped down before the market opened on Wednesday . The stock had previously closed at $19.09, but opened at $18.70. DICE Therapeutics shares last traded at $19.05, with a volume of 2,472 shares.
Analyst Upgrades and Downgrades
Several research firms have recently issued reports on DICE. Stifel Nicolaus started coverage on shares of DICE Therapeutics in a research report on Tuesday, September 6th. They set a "buy" rating and a $37.00 price objective on the stock. HC Wainwright started coverage on shares of DICE Therapeutics in a research note on Monday, July 18th. They set a "buy" rating and a $40.00 price objective for the company. Finally, Cantor Fitzgerald assumed coverage on shares of DICE Therapeutics in a research note on Wednesday, September 14th. They set an "overweight" rating and a $36.00 target price for the company. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, DICE Therapeutics currently has a consensus rating of "Buy" and an average target price of $43.33.
Get DICE Therapeutics alerts:DICE Therapeutics Trading Down 2.0 %
The business has a fifty day moving average price of $18.47 and a two-hundred day moving average price of $17.73. The firm has a market capitalization of $701.17 million and a PE ratio of -4.80.
Institutional Investors Weigh In On DICE Therapeutics
Several hedge funds and other institutional investors have recently made changes to their positions in DICE. Amalgamated Bank acquired a new position in DICE Therapeutics during the first quarter worth approximately $39,000. Prospera Financial Services Inc acquired a new position in DICE Therapeutics during the first quarter worth approximately $39,000. Legal & General Group Plc increased its position in DICE Therapeutics by 265.1% during the second quarter. Legal & General Group Plc now owns 4,764 shares of the company's stock worth $74,000 after buying an additional 3,459 shares during the period. Virtus ETF Advisers LLC increased its holdings in shares of DICE Therapeutics by 18.5% in the second quarter. Virtus ETF Advisers LLC now owns 7,482 shares of the company's stock valued at $116,000 after purchasing an additional 1,166 shares during the period. Finally, SG Americas Securities LLC acquired a new position in shares of DICE Therapeutics in the second quarter valued at approximately $131,000. Institutional investors and hedge funds own 95.42% of the company's stock.About DICE Therapeutics
(Get Rating)
DICE Therapeutics, Inc, a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Its platform DELSCAPE, is designed to discover selective oral small molecules to modulate protein-protein interactions (PPIs) as effectively as systemic biologics.
Recommended Stories
- Get a free copy of the StockNews.com research report on DICE Therapeutics (DICE)
- What Steelcase's Earnings Say About the Return to the Office?
- The Institutions Hold On To Darden Restaurants International
- These 3 Big Dividend Payers Also Boast Strong Price Growth
- Is The Golden Age Of Homebuilding Already Over?
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
Receive News & Ratings for DICE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DICE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
DICE Therapeutics, Inc. (NASDAQ:DICE – Get Rating) gapped down before the market opened on Wednesday . The stock had previously closed at $19.09, but opened at $18.70. DICE Therapeutics shares last traded at $19.05, with a volume of 2,472 shares.
周三开盘前，Dice治疗公司(纳斯达克：Dice-Get评级)股价下跌。该股此前收盘报19.09美元，开盘报18.70美元。Dice Treateutics的股票尾盘报19.05美元，成交量为2,472股。
Analyst Upgrades and Downgrades
分析师升级和下调评级
Several research firms have recently issued reports on DICE. Stifel Nicolaus started coverage on shares of DICE Therapeutics in a research report on Tuesday, September 6th. They set a "buy" rating and a $37.00 price objective on the stock. HC Wainwright started coverage on shares of DICE Therapeutics in a research note on Monday, July 18th. They set a "buy" rating and a $40.00 price objective for the company. Finally, Cantor Fitzgerald assumed coverage on shares of DICE Therapeutics in a research note on Wednesday, September 14th. They set an "overweight" rating and a $36.00 target price for the company. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, DICE Therapeutics currently has a consensus rating of "Buy" and an average target price of $43.33.
几家研究公司最近发布了关于骰子的报告。Stifel Nicolaus在9月6日星期二的一份研究报告中开始报道Dice治疗公司的股票。他们为该股设定了“买入”评级和37.00美元的目标价。HC Wainwright于7月18日星期一在一份研究报告中开始报道Dice治疗公司的股票。他们为该公司设定了“买入”评级和40.00美元的目标价。最后，坎托·菲茨杰拉德在9月14日星期三的一份研究报告中对Dice治疗公司的股票进行了报道。他们为该公司设定了“增持”评级和36.00美元的目标价。六位研究分析师对该股的评级为买入，根据MarketBeat.com的数据，Dice Treeutics目前的共识评级为“买入”，平均目标价为43.33美元。
DICE Therapeutics Trading Down 2.0 %
Dice Treeutics股价下跌2.0%
The business has a fifty day moving average price of $18.47 and a two-hundred day moving average price of $17.73. The firm has a market capitalization of $701.17 million and a PE ratio of -4.80.
该业务的50日移动平均价为18.47美元，200日移动平均价为17.73美元。该公司市值为7.0117亿美元，市盈率为-4.80。
Institutional Investors Weigh In On DICE Therapeutics
机构投资者参与Dice Treeutics
About DICE Therapeutics
关于骰子治疗公司
(Get Rating)
(获取评级)
DICE Therapeutics, Inc, a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Its platform DELSCAPE, is designed to discover selective oral small molecules to modulate protein-protein interactions (PPIs) as effectively as systemic biologics.
Dice Treateutics，Inc.是一家生物制药公司，建立了各种口服治疗候选药物，用于治疗免疫学和其他治疗领域的慢性病。其平台DELSCAPE旨在发现选择性口服小分子，以与系统生物学一样有效地调节蛋白质-蛋白质相互作用(PPI)。
Recommended Stories
推荐故事
- Get a free copy of the StockNews.com research report on DICE Therapeutics (DICE)
- What Steelcase's Earnings Say About the Return to the Office?
- The Institutions Hold On To Darden Restaurants International
- These 3 Big Dividend Payers Also Boast Strong Price Growth
- Is The Golden Age Of Homebuilding Already Over?
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- 免费获取StockNews.com关于DICE治疗(DICE)的研究报告
- 斯蒂尔凯斯的收益说明了他重返办公室的原因吗？
- 这些机构持有达顿餐饮国际公司的股份
- 这三大股利支付者也拥有强劲的价格增长
- 住房建设的黄金时代已经结束了吗？
- 天然气价格继续回升，这些股票应该会受益
Receive News & Ratings for DICE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DICE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受DICE治疗日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Dice Treateutics和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧